Search Browse Earnings

Keenova Therapeutics plc — SlamSEC

Keenova Therapeutics plc

Pharmaceutical Preparations·DUBLIN 15

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

$874.6M

-60.4% YoY

FY 2024

Adj. EBITDA

$264.0M

30.2% margin

FY 2024

Net Income

-$313.1M

-35.8% margin

FY 2024

EPS (Diluted)

-$3.69

FY 2024

Stock Price

—

52W Range

—

P/E Ratio

—

Market Cap

—

Cash

$297.9M

FY 2024

Total Debt

$3.5B

FY 2023

Net Debt

$3.2B

FY 2023

Enterprise Value

—

Debt / EBITDA

12.1x

FY 2024

EV / EBITDA

—

Employees

—

CFO

Stamoulis Christiana